KMK21 Apr 2017 18:23
Oh and here is rather more of the Midas article with no selective censoring.
"Kromek’s technology is used in devices including probes that can evaluate how and whether cancer is spreading in a patient and sophisticated machines that highlight conditions ranging from osteoporosis to heart disease.
Some of this equipment is already on the market and some is in development, but Kromek is working with is working with top medical suppliers to make CZT products available in hospitals around the world. Kromek joined AIM in October 2013 at 51p. In its first year as a public company, it disappointed investors with lower-than-expected revenues.
The shortfall arose because a couple of large orders were delayed from one year to the next, but the market was spooked and the share price suffered. Kromek will report annual figures to April in a couple of months and brokers forecast sales of £8.1million, rising to £8.4million next year.
Pre-tax losses of about £3million are expected, largely because the firm is still investing in research and development and sales are at an early stage.
Midas verdict: Investing in lossmaking firms can be high risk, but Kromek’s technology is ground-breaking, the firm is working with some of the biggest organisations in the world and prospects are bright. A potentially rewarding buy for brave investors. "